The partnership will develop the three Covid-19 vaccine candidates based on the horsepox vector platform. Credit: mattthewafflecat from Pixabay.

Tonix Pharmaceuticals has signed a research collaboration and exclusive licensing agreement with the University of Alberta in Canada for three new vaccine candidates to prevent Covid-19.

The partnership will develop the three vaccine candidates, which are based on the horsepox vector platform and designed to express various SARS-CoV-2 antigens.

Go deeper with GlobalData

Data Insights

The gold standard of business intelligence.

Find out more

In February this year, Tonix Pharmaceuticals collaborated with non-profit Southern Research to develop another Covid-19 vaccine candidate, TNX-1800, which is also based on horsepox vector platform but designed to express SARS-CoV-2 Spike protein.

The three newly licensed Covid-19 vaccine candidates are named TNX-1810, TNX-1820 and TNX-1830.

Horsepox is the vector system that forms the company’s TNX-801 potential vaccine for smallpox and monkeypox. TNX-801 has been developed to induce predominant T cell responses, while the new vaccine candidates are meant for pure T cell responses.

University of Alberta professor David Evans said: “TNX-1810, TNX-1820 and TNX-1830 are designed to express different protein antigens from SARS-CoV-2. It is currently unknown what type of vaccine and which antigens from SARS-CoV-2 will provide effective protection from Covid-19.

GlobalData Strategic Intelligence

US Tariffs are shifting - will you react or anticipate?

Don’t let policy changes catch you off guard. Stay proactive with real-time data and expert analysis.

By GlobalData

“Orthopoxviruses like horsepox induce strong innate and adaptive immunity and long-lasting T-cell immunity. We have designed TNX-1810, TNX-1820 and TNX-1830 to express and induce immunity to SARS-CoV-2 proteins that are different from Spike.”

Evans is the principal investigator of the TNX-1810, TNX-1820 and TNX-1830 research project.

As part of the research collaboration agreement, Tonix has gained from the University of Alberta an exclusive licence for technology and patents associated with TNX-1810, TNX-1820 and TNX-1830.

Tonix Pharmaceuticals plans to further assess the safety and efficacy of the new vaccine candidates in preventing Covid-19 infection.

Currently, the candidates are in the pre-investigational new drug (IND) application stage of development.

Pharmaceutical Technology Excellence Awards - Have you nominated?

Nominations are now open for the prestigious Pharmaceutical Technology Excellence Awards - one of the industry's most recognised programmes celebrating innovation, leadership, and impact. This is your chance to showcase your achievements, highlight industry advancements, and gain global recognition. Don't miss the opportunity to be honoured among the best - submit your nomination today!

Nominate Now